

AMG-337

Chemical Properties


CAS No. : 1173699-31-4

Formula: C23H22FN7O3

Molecular Weight: 463.46

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

| | |
|---------------|--|
| Description | AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337(AMG337) inhibits MET kinase activity (IC50: < 5 nM). |
| Targets(IC50) | c-Met/HGFR |
| In vitro | AMG 337 potently inhibits the enzymatic activity of WT MET and a subset of MET mutants found in papillary renal cell carcinoma. The inability of AMG 337 to inhibit the Y1230 and D1228 mutants is likely the result of a disruption of the inactive conformation of the activation loop in the MET kinase domain. AMG 337 also inhibits cell based HGF-induced MET phosphorylation in PC3 cells with IC50 of 5 nM. AMG 337 inhibits proliferation in MET-dependent cancer cell lines. AMG 337 inhibits signaling through the PI3K and MAPK pathways in MET-amplified gastric cancer cell lines resulting in profound effects on cell proliferation and survival[1]. |
| In vivo | AMG 337 exhibits impressive potency with >90% inhibition of Gab-1 phosphorylation at a dose of 0.75 mg/kg (32 nmol/L free-drug concentration). AMG 337 is well tolerated at continuously administered doses that corresponded with complete MET inhibition for 24 hours, suggesting that AMG 337 has the preClinical attributes required to test the role of MET in human cancer[1]. |
| Cell Research | To evaluate the effect of AMG 337 on viability, cells are seeded in 96-well plates at an optimal density to ensure proliferation throughout the duration of the experiments. Cells are treated for 72 hours with a 10-point, 3-fold, serial dilution of AMG 337 using a top concentration of 3 mmol/L. Viability is measured with the CellTiter-Glo Luminescent Cell Viability Assay.(Only for Reference) |

Solubility Information

| | |
|------------|--|
| Solubility | Ethanol: 95 mg/mL (204.98 mM),Sonication is recommended. DMSO: 50 mg/mL (107.88 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|--|

A DRUG SCREENING EXPERT

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.1577 mL | 10.7884 mL | 21.5768 mL |
| 5 mM | 0.4315 mL | 2.1577 mL | 4.3154 mL |
| 10 mM | 0.2158 mL | 1.0788 mL | 2.1577 mL |
| 50 mM | 0.0432 mL | 0.2158 mL | 0.4315 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Hughes PE, et al. Mol Cancer Ther. 2016, 15(7):1568-1579.

Huang Y, Guo Y, Zhou Y, et al. Tivantinib alleviates inflammatory diseases by directly targeting NLRP3. iScience. 2023

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481